Clinical Study on the Improvement of Myocardial Injury Complicated with Rheumatoid Arthritis by Tongluo Kaibi Tablets

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2025001415

Enrollment

Unknown

Registered

2025-07-16

Start date

2026-04-01

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Clinical control group:Leflunomide

Clinical trial group:Leflunomide, Tongluo Kaibi Tablets

Healthy control group:nothing

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Experimental group: Patients diagnosed with RA at the Rheumatology and Immunology Department of our hospital from January 2026 to December 2028. Inclusion criteria for RA: Adhere to the 2010 RA classification criteria of the American College of Rheumatology/European League Against Rheumatism. The syndrome of liver and kidney deficiency was formulated based on the "Group Standard for Rheumatoid Arthritis Symptoms and Diagnosis - Joint Diagnosis Guidelines" released by the Chinese Association of Traditional Chinese Medicine in 2017. Control group: Healthy individuals who underwent physical examinations at the hospital's health center from January 2026 to December 2028.

Exclusion criteria

Exclusion criteria: Experimental group: Patients diagnosed with RA at the Rheumatology and Immunology Department of our hospital from January 2026 to December 2028. RA inclusion criteria: Participants who meet the exclusion criteria of the American College of Rheumatology/European Working Group: those with a history of systemic rheumatic diseases chronic diseases (cardiovascular pulmonary kidney liver etc.) autoimmune inflammatory metabolic and infectious diseases as well as pregnant women and those receiving anti-lipid drugs (including statins). Control group exclusion criteria: Excluding participants with a history of systemic rheumatic diseases chronic diseases (cardiovascular pulmonary kidney liver etc.) autoimmune inflammatory metabolic and infectious diseases as well as pregnant women and those receiving anti-lipid drugs (including statins).

Design outcomes

Primary

Measure	Time frame
M2 macrophages;Interleukin-6;Cardiac Troponin T;a disintegrin and metalloproteases-like decysin-1;M1 macrophages;Tumour necrosis factor-a;Creatine Kinase;heart color ultrasound;	—

Countries

China

Contacts

Public Contactjingjing cao

Hebei General Hospital

caojingjingnv520@126.com15200027693

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026